search

Capricor Therapeutics Inc (CAPR)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
Capricor Stock Rises Despite Wider-Than-Expected Q3 Loss
Nov 11, 2026

Capricor Stock Rises Despite Wider-Than-Expected Q3 Loss

Capricor Therapeutics Inc. (NASDAQ: CAPR) shares are trading higher despite reporting a wider-than-expected loss of 73 cents per share for the third quarter. The company announced significant progress on its regulatory filing and launch readiness for deramiocel, its Duchenne muscular dystrophy treatment, which has an FDA decision date of Nov. 22, 2026. The stock is up over 15% following these updates.
Company relevance
100.00%
Company sentiment
Somewhat-Bullish
Overall sentiment
Somewhat-Bullish
FDA Decision Watch: Regeneron And Roche’s Autoimmune Drugs, Capricor’s DMD Therapy In Spotlight
Nov 2, 2026

FDA Decision Watch: Regeneron And Roche’s Autoimmune Drugs, Capricor’s DMD Therapy In Spotlight

November 2026 brings several significant FDA decisions, with Regeneron and Alnylam's Cemdisiran for generalized myasthenia gravis, Roche's Gazyva for primary membranous nephropathy, and Capricor Therapeutics' Deramiocel for DMD all under review. Cemdisiran and Gazyva have shown promising Phase 3 trial results, with Gazyva potentially becoming the first FDA-approved treatment for its indication. Roche also awaits a decision on its breast cancer drug, Giredestrant, which has a projected peak annual sales exceeding CHF3 billion.
Company relevance
93.86%
Company sentiment
Somewhat-Bullish
Overall sentiment
Bullish
CAPR Stock Rallies Into FDA Decision Month: Retail Spots Approval ‘Tea Leaves’ In Capricor’s Launch Team Hiring
Nov 1, 2026

CAPR Stock Rallies Into FDA Decision Month: Retail Spots Approval ‘Tea Leaves’ In Capricor’s Launch Team Hiring

Shares of Capricor Therapeutics (CAPR) surged as retail investors interpreted recent job postings for launch-related roles as an indicator of potential FDA approval for its Duchenne muscular dystrophy treatment, Deramiocel. The FDA's decision deadline is November 22, following an extension to review additional data focused on preserving arm and hand function. Despite a previous advisory panel vote against the treatment's effectiveness for a heart-related indication, the company remains optimistic about its upper-limb endpoint data.
Company relevance
100.00%
Company sentiment
Somewhat-Bullish
Overall sentiment
Somewhat-Bullish